Needham analyst Serge Belanger maintained a Hold rating on Adamas Pharmaceuticals (ADMS – Research Report) today. The company's shares closed last Tuesday at $8.07. According to TipRanks.com, Belanger is a 3-star analyst with an average return of 2.2% and a 41.3% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Amphastar Pharmaceuticals, and KalVista Pharmaceuticals. Adamas Pharmaceuticals has an analyst consensus of Hold, with a price target consensus of $8.37, implying a 4.0% upside from current levels. In a report released yesterday, JMP Securities also downgraded the stock to Hold. See the top stocks recommended by analysts >> Adamas Pharmaceuticals' market cap is currently $368M and has a P/E ratio of -2.70. The company has a Price to Book ratio of -44.27. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. Read More on ADMS: Tesla Stock: Should Investors Be Concerned with Volatility? The Hangover Isn’t Over for Boston Beer Stock Taking Stock of Levi Strauss’ Risk Factors H.C. Wainwright Thinks InflaRx’s Stock is Going to Recover Broadcom Stock: Growth at a More-than-Reasonable Price